Global Enoxaparin API Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Enoxaparin API Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Enoxaparin is made from heparin and is one type of the low molecular weight heparin (LMWH). It is used as an anticoagulant that prevents the formation of blood clots also known as ‘blood thinner’. It is used to treat various conditions including deep vein thrombosis (DVT), pulmonary embolism in the lungs, acute coronary syndrome and heart attack.
Enoxaparin API report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Enoxaparin API market is projected to reach US$ 1001.5 million in 2029, increasing from US$ 670 million in 2022, with the CAGR of 5.9% during the period of 2024 to 2029. Demand from COVID-19 and Pulmonary Embolism are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Enoxaparin API industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Enoxaparin API key manufacturers include Pfizer Inc., Sanofi S.A., GlaxoSmithKline Plc, Bristol Myer Squibb Company, Bohehringer Ingelheim, Eisai Inc., Teva Pharmaceutical Industries Ltd., Abbot India Limited, Novartis AG and ChemWerth, etc. Pfizer Inc., Sanofi S.A., GlaxoSmithKline Plc are top 3 players and held % sales share in total in 2022.
Enoxaparin API can be divided into Multi Vials, Pre-Filled Syringes and Others,, etc. Multi Vials is the mainstream product in the market, accounting for % sales share globally in 2022.
Enoxaparin API is widely used in various fields, such as COVID-19, Pulmonary Embolism, Atrial Fibrillation and Others, etc. COVID-19 provides greatest supports to the Enoxaparin API industry development. In 2022, global % sales of Enoxaparin API went into COVID-19 filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Enoxaparin API market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Pfizer Inc.
Sanofi S.A.
GlaxoSmithKline Plc
Bristol Myer Squibb Company
Bohehringer Ingelheim
Eisai Inc.
Teva Pharmaceutical Industries Ltd.
Abbot India Limited, Novartis AG
ChemWerth
Laboratorios Farmaceuticos ROVI SA
Gland Pharma Limited
Hanways Chempharma Co. Ltd
Changzhou Qianhong Biopharma
Shenzhen Hepalink Pharmaceutical Group
Segment by Type
Multi Vials
Pre-Filled Syringes
Others
COVID-19
Pulmonary Embolism
Atrial Fibrillation
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Enoxaparin API market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Enoxaparin API, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Enoxaparin API industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Enoxaparin API in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Enoxaparin API introduction, etc. Enoxaparin API Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Enoxaparin API market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Enoxaparin API report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Enoxaparin API market is projected to reach US$ 1001.5 million in 2029, increasing from US$ 670 million in 2022, with the CAGR of 5.9% during the period of 2024 to 2029. Demand from COVID-19 and Pulmonary Embolism are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Enoxaparin API industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Enoxaparin API key manufacturers include Pfizer Inc., Sanofi S.A., GlaxoSmithKline Plc, Bristol Myer Squibb Company, Bohehringer Ingelheim, Eisai Inc., Teva Pharmaceutical Industries Ltd., Abbot India Limited, Novartis AG and ChemWerth, etc. Pfizer Inc., Sanofi S.A., GlaxoSmithKline Plc are top 3 players and held % sales share in total in 2022.
Enoxaparin API can be divided into Multi Vials, Pre-Filled Syringes and Others,, etc. Multi Vials is the mainstream product in the market, accounting for % sales share globally in 2022.
Enoxaparin API is widely used in various fields, such as COVID-19, Pulmonary Embolism, Atrial Fibrillation and Others, etc. COVID-19 provides greatest supports to the Enoxaparin API industry development. In 2022, global % sales of Enoxaparin API went into COVID-19 filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Enoxaparin API market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Pfizer Inc.
Sanofi S.A.
GlaxoSmithKline Plc
Bristol Myer Squibb Company
Bohehringer Ingelheim
Eisai Inc.
Teva Pharmaceutical Industries Ltd.
Abbot India Limited, Novartis AG
ChemWerth
Laboratorios Farmaceuticos ROVI SA
Gland Pharma Limited
Hanways Chempharma Co. Ltd
Changzhou Qianhong Biopharma
Shenzhen Hepalink Pharmaceutical Group
Segment by Type
Multi Vials
Pre-Filled Syringes
Others
Segment by Application
COVID-19
Pulmonary Embolism
Atrial Fibrillation
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Enoxaparin API market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Enoxaparin API, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Enoxaparin API industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Enoxaparin API in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Enoxaparin API introduction, etc. Enoxaparin API Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Enoxaparin API market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices